Evidence map›Paper›PMID 38592453›Full record

ArticleCancer research communications2024

Overcoming Xenoantigen Immunity to Enable Cellular Tracking and Gene Regulation with Immune-competent "NoGlow" Mice.

Timothy N Trotter, Andrea Wilson, Jason McBane, Carina E Dagotto, Xiao-Yi Yang, Jun-Ping Wei, Gangjun Lei, Hannah Thrash, Joshua C Snyder, Herbert Kim Lyerly and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Timothy N TrotterDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0002-4579-943X
Andrea WilsonDepartment of Pathology, Duke University, Durham, North Carolina.ORCID 0000-0002-9773-6975
Jason McBaneDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0009-0003-7955-3977
Carina E DagottoDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0009-0003-3098-6317
Xiao-Yi YangDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0009-0000-5228-6459
Jun-Ping WeiDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0001-6311-6033
Gangjun LeiDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0002-0505-0475
Hannah ThrashDepartment of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.ORCID 0000-0002-0873-4434
Joshua C SnyderDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0002-9787-3371
Herbert Kim LyerlyDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0002-0063-4770
Zachary C HartmanDepartment of Surgery, Duke University, Durham, North Carolina.ORCID 0000-0001-6549-8207
Duke University · US

Funding

Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9M
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancersR01CA238217 · NCI · DUKE UNIVERSITY · PI HARTMAN, ZACHARY CONRAD · 2020 to 2024
$2.4M
Visualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancerR01CA255372 · NCI · DUKE UNIVERSITY · PI SNYDER, JOSHUA CLAIR · 2021 to 2025
$2.3M
NCI NIH HHS R01 CA238217NCI NIH HHS R01 CA255372NCI NIH HHS T32 CA009111
6 · The paper itself

Abstract

The ability to temporally regulate gene expression and track labeled cells makes animal models powerful biomedical tools. However, sudden expression of xenobiotic genes [e.g., GFP, luciferase (Luc), or rtTA3] can trigger inadvertent immunity that suppresses foreign protein expression or results in complete rejection of transplanted cells. Germline exposure to foreign antigens somewhat addresses these challenges; however, native fluorescence and bioluminescence abrogates the utility of reporter proteins and highly spatiotemporally restricted expression can lead to suboptimal xenoantigen tolerance. To overcome these unwanted immune responses and enable reliable cell tracking/gene regulation, we developed a novel mouse model that selectively expresses antigen-intact but nonfunctional forms of GFP and Luc, as well as rtTA3, after CRE-mediated recombination. Using tissue-specific CREs, we observed model and sex-based differences in immune tolerance to the encoded xenoantigens, illustrating the obstacles of tolerizing animals to foreign genes and validating the utility of these "NoGlow" mice to dissect mechanisms of central and peripheral tolerance. Critically, tissue unrestricted NoGlow mice possess no detectable background fluorescence or luminescence and exhibit limited adaptive immunity against encoded transgenic xenoantigens after vaccination. Moreover, we demonstrate that NoGlow mice allow tracking and tetracycline-inducible gene regulation of triple-transgenic cells expressing GFP/Luc/rtTA3, in contrast to transgene-negative immune-competent mice that eliminate these cells or prohibit metastatic seeding. Notably, this model enables de novo metastasis from orthotopically implanted, triple-transgenic tumor cells, despite high xenoantigen expression. Altogether, the NoGlow model provides a critical resource for in vivo studies across disciplines, including oncology, developmental biology, infectious disease, autoimmunity, and transplantation. SIGNIFICANCE: Multitolerant NoGlow mice enable tracking and gene manipulation of transplanted tumor cells without immune-mediated rejection, thus providing a platform to investigate novel mechanisms of adaptive immunity related to metastasis, immunotherapy, and tolerance.

Indexed as

Antigens, HeterophileCell TrackingAnimalsDisease Models, AnimalGene Expression RegulationMiceMice, TransgenicAntigens, Heterophile

Identifiers

PMID38592453
PMCPMC11003454
OpenAlexW4394602727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.